Fig 1.
* Statutory health insurance company; † Control group with PIM alternatives as stated in the PRISCUS publication. Patients receiving solely “other” drugs were prescribed neither a PIM nor a PIM alternative.
Fig 2.
Index date with preceding washout period and subsequent follow-up time.
PIM and PIM alternatives according to PRISCUS paper defined by ATC- and PZN-Code. ● End of individual follow-up after dispense date (maximum: 180 days).
Table 1.
Baseline characteristics of older adults classified as cases (PIM group) or controls (PIM alternatives).
Table 2.
Comparison of the type of admission to a hospital in cases (PIM group) and controls (PIM alternatives).
Table 3.
Polypharmacy in cases (PIM group) and controls (PIM alternatives).
Fig 3.
Eight most common PIM drug classes.
Table 4.
Incident hospitalizations during the 180-day follow-up period after the index date in cases (PIM group) and controls (PIM alternatives).
Table 5.
Hazard Ratios (HR) for hospitalization within 180 days after index date.
Fig 4.
Kaplan-Meier survival curves for hospitalization-free survival during the 180 days of follow-up.
Survival curves indicate an association between risk of all-cause hospitalization and use of PIMs.